Literature DB >> 21450488

Bronchial resection margin length and clinical outcome in non-small cell lung cancer.

Sandra C Tomaszek1, Yeonsoo Kim, Stephen D Cassivi, Matthew R Jensen, Keh-Hsien R Shen, Francis C Nichols, Claude Deschamps, Dennis A Wigle.   

Abstract

OBJECTIVE: Complete surgical resection with pathologic negative margin is associated with the best prognosis in early-stage non-small-cell lung cancer (NSCLC). However, the impact of the length of the bronchial margin remains unknown. This study aimed to determine whether an increased bronchial resection margin length is correlated with an improved disease-free and overall survival rate.
METHODS: A total of 3936 consecutive pulmonary resections were performed between 25 June 1992 and 31 December 2007 at Mayo Clinic Rochester. A subset consisting of 496 patients with completely resected lesions (R0-resection), and a documented bronchial margin length was analyzed retrospectively.
RESULTS: There were 340 men (68.5%) and 156 women (31.5%), with a mean age of 65.9±10.6 years. All patients underwent anatomic lobectomy or larger resection. Final pathology confirmed complete resection without microscopic residual tumor (R0-resection) in all patients. Mean length of the bronchial resection margin was 23.3±15.9mm. Overall, 190 patients (38.3%) suffered from disease recurrence with local recurrence in 35 patients, distant recurrence in 101, and both local and distant recurrence in 54 patients. Overall 5-year and 10-year local recurrence-free survival was 72.5% (95% confidence interval (CI): 67.3-78.1) and 68.0% (95% CI: 62.1-74.4), distant recurrence free survival 61.0% (95% CI: 55.8-66.6) and 52.9% (95% CI: 46.7-60.1) and overall survival 50.0% (95% CI: 45.1-55.3) and 28.8% (95% CI: 23.8-34.7). Tumor size and N-stage were associated with a worse prognosis in terms of local and distant recurrence, as well as survival (p<0.05). Histology was not significantly associated with local recurrence (p=0.28), though adenocarcinoma relative to squamous cell carcinoma was associated with an increased risk of distant recurrence (p<0.01). There was no significant association between type of surgical resection and local (p=0.37) or distant recurrence (p=0.37). Neither local (p=0.56) or distant recurrence (p=0.46), nor survival (p=0.54) was associated with the bronchial margin length. In multivariate models including age, N-stage, and gender there were no significant overall associations of margin length (≤5, 6-10, 11-15, 16-20, >20mm) and local recurrence (p=0.51), distant recurrence (p=0.33), or survival (p=0.75).
CONCLUSIONS: When complete surgical resection is achieved, the extent of the bronchial margin has no clinically relevant impact on disease-free and overall survival in NSCLC.
Copyright © 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21450488     DOI: 10.1016/j.ejcts.2011.02.042

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  10 in total

Review 1.  Surgical treatment of non-small-cell lung cancer in octogenarians.

Authors:  Miguel Guerra; Paulo Neves; José Miranda
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-02-08

2.  Topography of the sentinel node according to the affected lobe in lung cancer.

Authors:  J M Galbis-Caravajal; A Lafuente-Sanchis; M Estors-Guerrero; N Martinez-Hernández; C Fuster-Diana; A Cremades; Á Zúñiga
Journal:  Clin Transl Oncol       Date:  2017-01-27       Impact factor: 3.405

Review 3.  Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC).

Authors:  Bojan Zaric; Vladimir Stojsic; Aleksandar Tepavac; Tatjana Sarcev; Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Ilias Karapantzos; Georgios Kesisis; Ioanna Kougioumtzi; Nikolaos Katsikogiannis; Nikolaos Machairiotis; Aikaterini Stylianaki; Christophoros N Foroulis; Konstantinos Zarogoulidis; Branislav Perin
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

Review 4.  Lung cancer surgery: an up to date.

Authors:  Nikolaos Baltayiannis; Michail Chandrinos; Dimitrios Anagnostopoulos; Paul Zarogoulidis; Kosmas Tsakiridis; Andreas Mpakas; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

Review 5.  Surgical strategies in the therapy of non-small cell lung cancer.

Authors:  Feras Al-Shahrabani; Daniel Vallböhmer; Sebastian Angenendt; Wolfram T Knoefel
Journal:  World J Clin Oncol       Date:  2014-10-10

6.  An antiquated contraindication for minimally invasive lung surgery: No place to staple the bronchus.

Authors:  Tuğba Coşgun; Erkan Kaba; Kemal Ayalp; Alper Toker
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-10-23       Impact factor: 0.332

7.  The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.

Authors:  Yuan Wang; Guo-Fang Hu; Zhe-Hai Wang
Journal:  Onco Targets Ther       Date:  2017-07-19       Impact factor: 4.147

8.  Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma.

Authors:  Yunqiang Nie; Wei Gao; Na Li; Wenjun Chen; Hui Wang; Cuiyun Li; Haiyan Zhang; Ping Han; Yingmei Zhang; Xin Lv; Xinyi Xu; Hongyan Liu
Journal:  World J Surg Oncol       Date:  2017-03-03       Impact factor: 2.754

9.  Prognostic factors in completely resected lymph-node-negative pulmonary adenocarcinoma.

Authors:  Nussara Pakvisal; Poonchavist Chantranuwat; Chanida Vinayanuwattikun; Piyada Sitthideatphaiboon; Chinachote Teerapakpinyo; Shanop Shuangshoti; Vichai Benjacholamas; Nopporn Pornpattanarak; Virote Sriuranpong
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

10.  Postoperative radiation therapy for non-small cell lung cancer and thymic malignancies.

Authors:  Daniel R Gomez; Ritsuko Komaki
Journal:  Cancers (Basel)       Date:  2012-03-14       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.